Caseflicks

Supreme Court of the United States • 2005

Dura Pharmaceuticals, Inc. v. Broudo

544 U.S. 336 | 125 S. Ct. 1627 | 161 L. Ed. 2d 577 | 2005 U.S. LEXIS 3478 | 73 U.S.L.W. 4283 | 18 Fla. L. Weekly Fed. S 233

Full access

Unlock the video and quiz

The written brief is free to read below. Subscribe to watch the video explainer and take the quiz.

Create an account Log in

Takeaway

In short, this case requires securities-fraud plaintiffs to allege and prove that the fraud itself proximately caused a real economic loss; purchase-price inflation alone is not enough.

Background

Investors purchased Dura Pharmaceuticals stock in the public market between April 1997 and February 1998. They alleged that Dura made false statements about the expected profitability of its drug sales and the likelihood that the Food and Drug Administration would approve a new asthma-spray device.

On February 24, 1998, Dura announced lower-than-expected earnings, principally because of slow drug sales. Its stock price fell from about $39 to about $21 the next day. About eight months later, Dura disclosed that the FDA would not approve the spray device. The stock price fell temporarily after that announcement but substantially recovered within a week.

The investors' complaint alleged, with respect to the spray-device statements, that they paid artificially inflated prices for Dura securities and suffered damages. The District Court dismissed the claim for failure adequately to plead loss causation. The Ninth Circuit reversed, holding that loss causation was established if the stock price was inflated by the misrepresentation when the plaintiffs bought it. The Supreme Court granted review to resolve a conflict among the circuits.

Issues

Issue #1

Whether a securities-fraud plaintiff can prove loss causation merely by showing that the defendant's misrepresentation inflated the security's price at the time of purchase.

Holding

No. An inflated purchase price alone neither constitutes nor proximately causes the economic loss required for a private action under § 10(b) and Rule 10b-5.

Reasoning

In a fraud-on-the-market case, paying an inflated price does not itself establish a loss at the moment of purchase. The buyer's payment is offset by ownership of stock with an equivalent market value at that time. An actionable claim requires both economic loss and a causal connection between the misrepresentation and that loss.

A later decline in the stock's price does not necessarily result from the earlier fraud. The investor may sell before the truth reaches the market, or the later decline may stem from changing market conditions, investor expectations, industry developments, or company-specific events unrelated to the misstatement. Thus, purchase-price inflation may be related to a later loss, but merely "touching upon" a loss is not the same as causing it.

The Court's conclusion accords with the common-law roots of the implied securities-fraud action. Common-law deceit requires actual pecuniary damage proximately caused by the fraudulent statement, and other circuits had likewise rejected the view that inflation at purchase, standing alone, satisfies loss causation.

The Private Securities Litigation Reform Act confirms that result. It expressly places on the plaintiff the burden to prove that the defendant's act or omission caused the loss for which the plaintiff seeks recovery. Permitting recovery solely because a purchase price was inflated would improperly turn federal securities law into insurance against ordinary market losses rather than a remedy for losses fraud actually caused.

Issue #2

Whether the investors adequately pleaded economic loss and loss causation for the alleged misstatements about FDA approval of the asthma-spray device.

Holding

No. The complaint did not give fair notice of any economic loss caused by the spray-device misrepresentations beyond the legally insufficient assertion of an artificially inflated purchase price.

Reasoning

Even assuming that ordinary Rule 8 notice pleading governs loss causation and economic loss, a complaint must still provide fair notice of the claim and the grounds on which it rests. A plaintiff who suffered a fraud-caused economic loss should be able to identify, at least generally, the loss and the alleged causal connection.

The complaint's sole meaningful allegation concerning the spray-device claim was that the investors paid artificially inflated prices and suffered damages. It did not allege that Dura's stock price fell significantly when the FDA denial became known, nor did it identify another loss caused by disclosure of the truth.

Because an inflated purchase price is not itself the relevant economic loss, the complaint failed to allege what loss the plaintiffs suffered and how Dura's spray-device statements proximately caused it. Allowing such a bare allegation would invite the discovery-driven, weak claims that the Reform Act sought to curb and would create settlement pressure untethered to a plausibly pleaded injury.